PMID- 29487566
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220408
IS  - 1664-2392 (Print)
IS  - 1664-2392 (Electronic)
IS  - 1664-2392 (Linking)
VI  - 9
DP  - 2018
TI  - Islet Cell Associated Autoantibodies and C-Peptide Levels in Patients with 
      Diabetes and Symptoms of Gastroparesis.
PG  - 32
LID - 10.3389/fendo.2018.00032 [doi]
LID - 32
AB  - INTRODUCTION: Individuals with diabetes are at increased risk for complications, 
      including gastroparesis. Type 1 diabetes mellitus (T1DM) is an autoimmune 
      disorder resulting in decreased beta-cell function. Glutamic acid 
      decarboxylase-65 antibody (GADA) is the most commonly used test to assess 
      autoimmunity while C-peptide level is used to assess beta-cell function. Patients 
      with type 2 diabetes mellitus (T2DM), who are GADA positive, are labeled latent 
      autoimmune diabetes in adults (LADA). OBJECTIVE: To characterize patients with T1 
      and T2DM who have symptoms of gastroparesis using GADA and C-peptide levels and 
      to look for association with the presence of gastroparesis and its symptom 
      severity. DESIGN: 113 T1DM and 90 T2DM patients with symptoms suggestive of 
      gastroparesis were studied. Symptom severity was assessed using Gastroparesis 
      Cardinal Symptom Index (GCSI). Serum samples were analyzed for GADA and 
      C-peptide. RESULTS: Delayed gastric emptying was present in 91 (81%) of T1DM and 
      60 (67%) of T2DM patients (p = 0.04). GADA was present in 13% of T2DM subjects 
      [10% in delayed gastric emptying and 20% in normal gastric emptying (p = 0.2)]. 
      Gastric retention and GCSI scores were mostly similar in GADA positive and 
      negative T2DM patients. GADA was present in 45% of T1DM subjects [46% in delayed 
      gastric emptying and 41% in normal gastric emptying (p = 0.81)]. Low C-peptide 
      levels were seen in 79% T1DM patients and 8% T2DM. All seven T2DM patients with 
      low C-peptide were taking insulin compared to 52% of T2DM with normal C-peptide. 
      CONCLUSION: GADA was present in 13% while low C-peptide was seen in 8% of our 
      T2DM patients with symptoms of gastroparesis. Neither did correlate with degree 
      of delayed gastric emptying or symptom severity. CLINICALTRIALSGOV IDENTIFIER: 
      NCT01696747.
FAU - Siraj, Elias S
AU  - Siraj ES
AD  - Division of Endocrinology and Metabolic Disorders, Eastern Virginia Medical 
      School, Norfolk, VA, United States.
FAU - Homko, Carol
AU  - Homko C
AD  - Lewis Katz School of Medicine, Temple University, Philadelphia, PA, United 
      States.
FAU - Wilson, Laura A
AU  - Wilson LA
AD  - Johns Hopkins University, Baltimore, MD, United States.
FAU - May, Patrick
AU  - May P
AD  - Johns Hopkins University, Baltimore, MD, United States.
FAU - Rao, Ajay D
AU  - Rao AD
AD  - Lewis Katz School of Medicine, Temple University, Philadelphia, PA, United 
      States.
FAU - Calles, Jorge
AU  - Calles J
AD  - Case Western Reserve University, Cleveland, OH, United States.
FAU - Farrugia, Gianrico
AU  - Farrugia G
AD  - Mayo Clinic, Rochester, NY, United States.
FAU - Hasler, William L
AU  - Hasler WL
AD  - University of Michigan, Ann Arbor, MI, United States.
FAU - Koch, Kenneth L
AU  - Koch KL
AD  - Wake Forest University, Winston-Salem, NC, United States.
FAU - Nguyen, Linda
AU  - Nguyen L
AD  - Stanford University, Palo Alto, CA, United States.
FAU - Snape, William J
AU  - Snape WJ
AD  - California Pacific Medical Center, San Francisco, CA, United States.
FAU - Abell, Thomas L
AU  - Abell TL
AD  - University of Louisville, Louisville, KY, United States.
FAU - Sarosiek, Irene
AU  - Sarosiek I
AD  - Texas Tech University Health Science Center, El Paso, TX, United States.
FAU - McCallum, Richard W
AU  - McCallum RW
AD  - Texas Tech University Health Science Center, El Paso, TX, United States.
FAU - Pasricha, Pankaj J
AU  - Pasricha PJ
AD  - Johns Hopkins University, Baltimore, MD, United States.
FAU - Clarke, John
AU  - Clarke J
AD  - Johns Hopkins University, Baltimore, MD, United States.
FAU - Tonascia, James
AU  - Tonascia J
AD  - Johns Hopkins University, Baltimore, MD, United States.
FAU - Hamilton, Frank
AU  - Hamilton F
AD  - National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 
      United States.
FAU - Parkman, Henry P
AU  - Parkman HP
AD  - Lewis Katz School of Medicine, Temple University, Philadelphia, PA, United 
      States.
LA  - eng
SI  - ClinicalTrials.gov/NCT01696747
GR  - U01 DK074007/DK/NIDDK NIH HHS/United States
GR  - U01 DK074035/DK/NIDDK NIH HHS/United States
GR  - U01 DK112193/DK/NIDDK NIH HHS/United States
GR  - U24 DK074008/DK/NIDDK NIH HHS/United States
PT  - Journal Article
DEP - 20180213
PL  - Switzerland
TA  - Front Endocrinol (Lausanne)
JT  - Frontiers in endocrinology
JID - 101555782
PMC - PMC5816742
OTO - NOTNLM
OT  - C-peptide
OT  - GAD
OT  - GAD65
OT  - GAD65 antibodies
OT  - diabetic gastroparesis
OT  - gastric emptying
OT  - gastroparesis
OT  - islet cell antibodies
EDAT- 2018/03/01 06:00
MHDA- 2018/03/01 06:01
PMCR- 2018/01/01
CRDT- 2018/03/01 06:00
PHST- 2017/10/19 00:00 [received]
PHST- 2018/01/23 00:00 [accepted]
PHST- 2018/03/01 06:00 [entrez]
PHST- 2018/03/01 06:00 [pubmed]
PHST- 2018/03/01 06:01 [medline]
PHST- 2018/01/01 00:00 [pmc-release]
AID - 10.3389/fendo.2018.00032 [doi]
PST - epublish
SO  - Front Endocrinol (Lausanne). 2018 Feb 13;9:32. doi: 10.3389/fendo.2018.00032. 
      eCollection 2018.